Education
About Us
Working with TipRanks
Follow Us
Vertex Pharmaceuticals (VRTX)
NASDAQ:VRTX
VRTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$362.50 - $519.88
Previous CloseN/A
Volume295.43K
Average Volume (3M)2.14M
Market Cap
$99.62B
Enterprise Value$110.40B
Total Cash (Recent Filing)$6.38B
Total Debt (Recent Filing)$1.53B
Price to Earnings (P/E)27.8
Beta0.64
Next Earnings
Oct 29, 2025EPS Estimate
4.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.52
Shares Outstanding256,390,660
10 Day Avg. Volume1,428,822
30 Day Avg. Volume2,142,557
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.11
Enterprise Value/Revenue9.67
Enterprise Value/Gross Profit11.23
Enterprise Value/Ebitda23.62
Forecast
1Y Price Target
$486.33Price Target Upside22.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering25
Bulls Say, Bears Say
Bulls Say
Pipeline ConfidenceRecent updates in VX-548 and VX-147 have been encouraging and reinforce confidence in Vertex's pipeline.
Prescription GrowthGrowth for Journavx scripts strengthens with TRx increasing by 3% and NRx also showing continued gains.
Regulatory EnvironmentFDA draft guidance highlights a path forming for PNP indication approvals and interest in providing non-opioid options.
Bears Say
Market Launch ChallengesA lighter week likely reflects early launch noise rather than a decline in underlying demand, with TRx down 2%.
Regulatory ChallengesVertex announced that the FDA informed the company that it does not see a path to a broad peripheral neuropathic pain label at this time.
Vertex Pharmaceuticals News
VRTX FAQ
What was Vertex Pharmaceuticals’s price range in the past 12 months?
Vertex Pharmaceuticals lowest stock price was $362.50 and its highest was $519.88 in the past 12 months.
What is Vertex Pharmaceuticals’s market cap?
Vertex Pharmaceuticals’s market cap is $99.62B.
When is Vertex Pharmaceuticals’s upcoming earnings report date?
Vertex Pharmaceuticals’s upcoming earnings report date is Oct 29, 2025 which is in 46 days.
How were Vertex Pharmaceuticals’s earnings last quarter?
Vertex Pharmaceuticals released its earnings results on Aug 06, 2025. The company reported $4.52 earnings per share for the quarter, beating the consensus estimate of $4.272 by $0.248.
Is Vertex Pharmaceuticals overvalued?
According to Wall Street analysts Vertex Pharmaceuticals’s price is currently Undervalued.
Does Vertex Pharmaceuticals pay dividends?
Vertex Pharmaceuticals does not currently pay dividends.
What is Vertex Pharmaceuticals’s EPS estimate?
Vertex Pharmaceuticals’s EPS estimate is 4.6.
How many shares outstanding does Vertex Pharmaceuticals have?
Vertex Pharmaceuticals has 256,390,660 shares outstanding.
What happened to Vertex Pharmaceuticals’s price movement after its last earnings report?
Vertex Pharmaceuticals reported an EPS of $4.52 in its last earnings report, beating expectations of $4.272. Following the earnings report the stock price went down -2.598%.
Which hedge fund is a major shareholder of Vertex Pharmaceuticals?
Currently, no hedge funds are holding shares in VRTX
Vertex Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$486.33 (22.39% Upside)
$486.33 (22.39% Upside)
Blogger Sentiment
Bullish
VRTX Sentiment 94%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 67.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $5.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.46%
12-Months-Change
Fundamentals
Return on Equity
22.77%
Trailing 12-Months
Asset Growth
19.39%
Trailing 12-Months
Company Description
Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on the discovery, development, and commercialization of innovative medicines for serious diseases. Headquartered in Boston, Massachusetts, Vertex primarily operates in the field of cystic fibrosis (CF) and has expanded its research to include other serious diseases, including sickle cell disease and beta-thalassemia. The company is known for its core products, including Trikafta, Kalydeco, and Orkambi, which are designed to treat the underlying causes of CF by targeting specific genetic mutations.
VRTX Company Deck
VRTX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment due to Vertex's strong revenue growth, successful product launches, and advancements in its pipeline. However, challenges in the pain program and increased operational expenses present notable concerns.View all VRTX earnings summariesVRTX Revenue Breakdown
60.66% U.S.
39.34% Europe
VRTX Stock 12 Month Forecast
Average Price Target
$486.33
▲(22.39% Upside)
Technical Analysis
Ownership Overview
0.23% Insiders
37.94% Mutual Funds
33.26% Other Institutional Investors
2.30% Public Companies and Individual Investors